Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
First Claim
Patent Images
1. A composition comprising:
- (a) nanoparticles of 7-t-butoxyiminomethylcamptothecin;
(b) at least one surface stabilizer, wherein the nanoparticles have an effective average particle size of less than about 4,000 nm; and
(c) showing at least a 1.5-fold better bioavailability than the unformulated drug in a subject.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to nanoparticulate compositions in which the active agent is a topoisomerase I inhibitor and pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer.
-
Citations
29 Claims
-
1. A composition comprising:
-
(a) nanoparticles of 7-t-butoxyiminomethylcamptothecin; (b) at least one surface stabilizer, wherein the nanoparticles have an effective average particle size of less than about 4,000 nm; and (c) showing at least a 1.5-fold better bioavailability than the unformulated drug in a subject. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
- 12. A method of making a nanoparticulate composition comprising contacting 7-t-butoxyiminomethylcamptothecin with at least one surface stabilizer for a time and under conditions sufficient to provide a nanoparticulate composition having an effective average particle size of less than about 4,000 nm.
- 19. A method of treating a proliferative disease comprising administrating to a patient in need thereof a formulation comprising nanoparticles of 7-t-butoxyiminomethylcamptothecin and at least one surface stabilizer, wherein the nanoparticles have an effective average particle size of less than about 4,000 nm.
- 27. A dosage form comprising 0.001-100 mg by weight of 7-t-butoxyiminomethylcamptothecin.
Specification